Posts tagged Piper
Analysts start Tactile Systems at buy, outperform

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively.

Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000 shares at $10 apiece earlier this month. The stock was changing hands at $12.98 at mid-day Monday.

Read More
Piper starts ReWalk Robotics at overweight

Piper Jaffray initiated coverage of ReWalk Robotics (NASDAQ:RWLK) with an “overweight” rating and price target of $10. The stock closed at $7.02 on Thursday.

“While the exoskeleton market for personal use is in what we would categorize as the market creation phase, which carries a higher degree of risk and volatility, we believe ReWalk has the first mover advantage, best technology and a solid business plan to further penetrate this large, relatively untapped market,” writes analyst Matt O’Brien.

Read More
Piper resumes coverage of NxStage Medical at overweight

Piper Jaffray has resumed coverage of NxStage Medical (NASDAQ:NXTM) with an “overweight” rating and $18.50 price target, down from $23 previously. The stock closed at $14.96 on Wednesday.

“We have known the story since its late 2005 IPO and watched the evolution of the business from one focused on hospital and home hemodialysis (HHD) to one that can provide virtually all the supplies clinicians and patients need to treat end-stage renal failure,” writes analyst Matt O’Brien.

Read More